Skip to main content
Premium Trial:

Request an Annual Quote

Former Onyx Executive William Gerber Named DiaDexus President, CEO


SANTA CLARA, Calif.--DiaDexus, a new company here formed as a joint venture between SmithKline Beecham and Incyte Pharmaceuticals and dedicated to the discovery and commericalization of novel molecular diagnostic products, announced the appointment of William Gerber to the post of president and CEO. Gerber joined DiaDexus from Onyx Pharmaceuticals where he was vice-president and chief operating officer. Previous to that, Gerber was president of Chiron Diagnostics, held various positions with Cetus, and was a practicing physician.

SmithKline's Chief Science and Technology Officer George Poste said that Gerber will help DiaDexus emerge "as a formidable competitor in molecular diagnostics and pharmacogenomics." SmithKline and Incyte each hold a 50 percent equity interest in the company. Incyte provides DiaDexus with nonexclusive access to its human and microbial databases, bioinformatics capabilities, and certain array technologies.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.